Genetic variation in normal tissue toxicity induced by ionizing radiation

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 667, Issue 1-2, 2009, Pages 58-69

  Popanda, Odilia ^a   Marquardt, Jens Uwe ^a   Chang Claude, Jenny ^a   Schmezer, Peter ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Fibrosis; Radiosensitivity; Single nucleotide polymorphism; Telangiectasia

Indexed keywords

ARTICLE; BRAIN TUMOR; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; DNA POLYMORPHISM; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HEAD AND NECK CANCER; HUMAN; IONIZING RADIATION; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RADIATION RESPONSE; RADIOSENSITIVITY; TISSUE DEGENERATION;

DNA REPAIR; GENETIC MARKERS; GENETIC VARIATION; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIATION INJURIES; RADIATION TOLERANCE; RADIOTHERAPY;

EID: 67649198795     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2008.10.014     Document Type: Article

References (84)

1. Radiotherapy, in: B.W. Stewart, P. Kleihues (Eds.), World Cancer Report, IARC Press, International Agency for Research on Cancer (IARC), World Health Organisation (WHO), Lyon, 2003, pp. 277-280.
2. Bentzen S.M., Dorr W., Anscher M.S., Denham J.W., Hauer-Jensen M., Marks L.B., and Williams J. Normal tissue effects: reporting and analysis. Semin. Radiat. Oncol. 13 (2003) 189-202
3. Dirier A., Akmansu M., Bora H., and Gurer M. The effect of vitamin E on acute skin reaction caused by radiotherapy. Clin. Exp. Dermatol. 32 (2007) 571-573
4. Momm F., Weissenberger C., Bartelt S., and Henke M. Moist skin care can diminish acute radiation-induced skin toxicity. Strahlenther. Onkol. 179 (2003) 708-712
5. Dorr W., and Hendry J.H. Consequential late effects in normal tissues. Radiother. Oncol. 61 (2001) 223-231
6. Lilla C., Ambrosone C.B., Kropp S., Helmbold I., Schmezer P., von Fournier D., Haase W., Sautter-Bihl M.L., Wenz F., and Chang-Claude J. Predictive factors for late normal tissue complications following radiotherapy for breast cancer. Breast Cancer Res. Treat. (2007) 143-150
7. Twardella D., Popanda O., Helmbold I., Ebbeler R., Benner A., von Fournier D., Haase W., Sautter-Bihl M.L., Wenz F., Schmezer P., and Chang-Claude J. Personal characteristics, therapy modalities and individual DNA repair capacity as predictive factors of acute skin toxicity in an unselected cohort of breast cancer patients receiving radiotherapy. Radiother. Oncol. 69 (2003) 145-153
8. Gatti R.A. The inherited basis of human radiosensitivity. Acta Oncol. 40 (2001) 702-711
9. Travis E.L. Genetic susceptibility to late normal tissue injury. Semin. Radiat. Oncol. 17 (2007) 149-155
10. Lindsay K.J., Coates P.J., Lorimore S.A., and Wright E.G. The genetic basis of tissue responses to ionizing radiation. Br. J. Radiol. 80 Spec No 1 (2007) S2-S6
11. Gudkov A.V., and Komarova E.A. The role of p53 in determining sensitivity to radiotherapy. Nat. Rev. Cancer 3 (2003) 117-129
12. Komarova E.A., Christov K., Faerman A.I., and Gudkov A.V. Different impact of p53 and p21 on the radiation response of mouse tissues. Oncogene 19 (2000) 3791-3798
13. Andreassen C.N., Alsner J., and Overgaard J. Does variability in normal tissue reactions after radiotherapy have a genetic basis-where and how to look for it?. Radiother. Oncol. 64 (2002) 131-140
14. Andreassen C.N., Alsner J., Overgaard M., and Overgaard J. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother. Oncol. 69 (2003) 127-135
15. Bartsch H., Dally H., Popanda O., Risch A., and Schmezer P. Genetic risk profiles for cancer susceptibility and therapy response. Recent Results Cancer Res. 174 (2007) 19-36
16. Hümmerich J., Werle-Schneider G., Popanda O., Celebi O., Chang-Claude J., Kropp S., Mayer C., Debus J., Bartsch H., and Schmezer P. Constitutive mRNA expression of DNA repair-related genes as a biomarker for clinical radiosensitivity: A pilot study in prostate cancer patients receiving radiotherapy. Int. J. Radiat. Biol. (2006) 593-604
17. West C.M., Elliott R.M., and Burnet N.G. The genomics revolution and radiotherapy. Clin. Oncol. (R. Coll. Radiol.) 19 (2007) 470-480
18. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys. 31 (1995) 1341-1346
19. Pavy J.J., Denekamp J., Letschert J., Littbrand B., Mornex F., Bernier J., Gonzales-Gonzales D., Horiot J.C., Bolla M., Bartelink H., and EORTC Late Effects Working Group. Late Effects toxicity scoring: the SOMA scale. Int. J. Radiat. Oncol. Biol. Phys. 31 (1995) 1043-1047
20. Bentzen S.M. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat. Rev. Cancer 6 (2006) 702-713
21. Andreassen C.N. Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles?. Acta Oncol. 44 (2005) 801-815
22. Stieber V.W., and Mehta M.P. Advances in radiation therapy for brain tumors. Neurol. Clin. 25 (2007) 1005-1033 ix
23. Valery C.A., Cornu P., Noel G., Duyme M., Boisserie G., Sakka L.J., Mazeron J.J., and van Effenterre R. Predictive factors of radiation necrosis after radiosurgery for cerebral metastases. Stereotact. Funct. Neurosurg. 81 (2003) 115-119
24. Distel L., Neubauer S., Varon R., Holter W., and Grabenbauer G. Fatal toxicity following radio- and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen breakage syndrome. Med. Pediatr. Oncol. 41 (2003) 44-48
25. Simon M., Ludwig M., Fimmers R., Mahlberg R., Muller-Erkwoh A., Koster G., and Schramm J. Variant of the CHEK2 gene as a prognostic marker in glioblastoma multiforme. Neurosurgery 59 (2006) 1078-1085
26. Ward J.F. Ionizing radiation damage to DNA. In: Dizdaroglu M., and Karakaya A.E. (Eds). Advances in DNA Damage and Repair (1999), Kluwer Academic/Plenum Publishers, New York 431-439
27. Ambrosone C.B., Tian C., Ahn J., Kropp S., Helmbold I., von Fournier D., Haase W., Sautter-Bihl M.L., Wenz F., and Chang-Claude J. Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study. Breast Cancer Res. 8 (2006) R40
28. Edvardsen H., Kristensen V.N., Grenaker Alnaes G.I., Bohn M., Erikstein B., Helland A., Borresen-Dale A.L., and Fossa S.D. Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 67 (2007) 1163-1171
29. Kuptsova N., Chang-Claude J., Kropp S., Helmbold I., Schmezer P., von Fournier D., Haase W., Sautter-Bihl M.L., Wenz F., Onel K., and Ambrosone C.B. Genetic predictors of long-term toxicities after radiation therapy for breast cancer. Int. J. Cancer 122 (2008) 1333-1339
30. Ahn J., Ambrosone C.B., Kanetsky P.A., Tian C., Lehman T.A., Kropp S., Helmbold I., von Fournier D., Haase W., Sautter-Bihl M.L., Wenz F., and Chang-Claude J. Polymorphisms in genes related to oxidative stress (CAT, MnSOD, MPO, and eNOS) and acute toxicities from radiation therapy following lumpectomy for breast cancer. Clin. Cancer Res. 12 (2006) 7063-7070
31. Fenster C.P., Weinsier R.L., Darley-Usmar V.M., and Patel R.P. Obesity, aerobic exercise, and vascular disease: the role of oxidant stress. Obes. Res. 10 (2002) 964-968
32. Fukumura D., Kashiwagi S., and Jain R.K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 6 (2006) 521-534
33. Prud'homme G.J. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab. Invest. 87 (2007) 1077-1091
34. Wynn T.A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 117 (2007) 524-529
35. Feltl D., Zavadova E., Pala M., and Hozak P. Post-treatment plasma transforming growth factor beta 1 (TGF-beta1) level predicts for late morbidity in patients with advanced head and neck cancer. Neoplasma 52 (2005) 393-397
36. Li C., Wilson P.B., Levine E., Barber J., Stewart A.L., and Kumar S. TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis. Int. J. Cancer 84 (1999) 155-159
37. Zhao L., Sheldon K., Chen M., Yin M.S., Hayman J.A., Kalemkerian G.P., Arenberg D., Lyons S.E., Curtis J.L., Davis M., Cease K.B., Brenner D., Anscher M.S., Lawrence T.S., and Kong F.M. The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer 59 (2008) 232-239
38. Grainger D.J., Heathcote K., Chiano M., Snieder H., Kemp P.R., Metcalfe J.C., Carter N.D., and Spector T.D. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum. Mol. Genet. 8 (1999) 93-97
39. Andreassen C.N., Alsner J., Overgaard J., Herskind C., Haviland J., Owen R., Homewood J., Bliss J., and Yarnold J. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother. Oncol. 75 (2005) 18-21
40. Andreassen C.N., Alsner J., Overgaard M., Sorensen F.B., and Overgaard J. Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM-a study based on DNA from formalin fixed paraffin embedded tissue samples. Int. J. Radiat. Biol. 82 (2006) 577-586
41. Quarmby S., Fakhoury H., Levine E., Barber J., Wylie J., Hajeer A.H., West C., Stewart A., Magee B., and Kumar S. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int. J. Radiat. Biol. 79 (2003) 137-143
42. Giotopoulos G., Symonds R.P., Foweraker K., Griffin M., Peat I., Osman A., and Plumb M. The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br. J. Cancer 96 (2007) 1001-1007
43. De Ruyck K., Van Eijkeren M., Claes K., Bacher K., Vral A., De Neve W., and Thierens H. TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int. J. Radiat. Oncol. Biol. Phys. 65 (2006) 1240-1248
44. Damaraju S., Murray D., Dufour J., Carandang D., Myrehaug S., Fallone G., Field C., Greiner R., Hanson J., Cass C.E., and Parliament M. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin. Cancer Res. 12 (2006) 2545-2554
45. Peters C.A., Stock R.G., Cesaretti J.A., Atencio D.P., Peters S., Burri R.J., Stone N.N., Ostrer H., and Rosenstein B.S. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 70 (2008) 752-759
46. Suga T., Ishikawa A., Kohda M., Otsuka Y., Yamada S., Yamamoto N., Shibamoto Y., Ogawa Y., Nomura K., Sho K., Omura M., Sekiguchi K., Kikuchi Y., Michikawa Y., Noda S., Sagara M., Ohashi J., Yoshinaga S., Mizoe J., Tsujii H., Iwakawa M., and Imai T. Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 69 (2007) 685-693
47. Lavin M.F., Gueven N., Bottle S., and Gatti R.A. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br. Med. Bull. 81-82 (2007) 129-147
48. Morgan J.L., Holcomb T.M., and Morrissey R.W. Radiation reaction in ataxia telangiectasia. Am. J. Dis. Child 116 (1968) 557-558
49. Cann K.L., and Hicks G.G. Regulation of the cellular DNA double-strand break response. Biochem. Cell Biol. 85 (2007) 663-674
50. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 3 (2003) 155-168
51. Parshad R., Sanford K.K., Jones G.M., and Tarone R.E. G2 chromosomal radiosensitivity of ataxia-telangiectasia heterozygotes. Cancer Genet. Cytogenet. 14 (1985) 163-168
52. Paterson M.C., MacFarlane S.J., Gentner N.E., and Smith B.P. Cellular hypersensitivity to chronic gamma-radiation in cultured fibroblasts from ataxia-telangiectasia heterozygotes. Kroc. Found. Ser. 19 (1985) 73-87
53. Angele S., Romestaing P., Moullan N., Vuillaume M., Chapot B., Friesen M., Jongmans W., Cox D.G., Pisani P., Gerard J.P., and Hall J. ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res. 63 (2003) 8717-8725
54. Andreassen C.N., Overgaard J., Alsner J., Overgaard M., Herskind C., Cesaretti J.A., Atencio D.P., Green S., Formenti S.C., Stock R.G., and Rosenstein B.S. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 64 (2006) 776-783
55. Ho A.Y., Fan G., Atencio D.P., Green S., Formenti S.C., Haffty B.G., Iyengar P., Bernstein J.L., Stock R.G., Cesaretti J.A., and Rosenstein B.S. Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 69 (2007) 677-684
56. Edvardsen H., Tefre T., Jansen L., Vu P., Haffty B.G., Fossa S.D., Kristensen V.N., and Borresen-Dale A.L. Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence. Radiat. Oncol. 2 (2007) 25
57. Iannuzzi C.M., Atencio D.P., Green S., Stock R.G., and Rosenstein B.S. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int. J. Radiat. Oncol. Biol. Phys. 52 (2002) 606-613
58. Bremer M., Klopper K., Yamini P., Bendix-Waltes R., Dork T., and Karstens J.H. Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects. Radiother. Oncol. 69 (2003) 155-160
59. Cesaretti J.A., Stock R.G., Lehrer S., Atencio D.A., Bernstein J.L., Stone N.N., Wallenstein S., Green S., Loeb K., Kollmeier M., Smith M., and Rosenstein B.S. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 61 (2005) 196-202
60. Rosenstein B.S., Cesaretti J.A., Stock R.G., Stone N.N., Atencio D.P., Peters C.A., Burri R., and Peters S. A validation study to examine the correlation between possession of variants in the ATM gene with the development of erectile dysfunction in prostate cancer patients treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 69 3 (2008) S29
61. Cesaretti J.A., Stock R.G., Atencio D.P., Peters S.A., Peters C.A., Burri R.J., Stone N.N., and Rosenstein B.S. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 68 (2007) 1410-1416
62. Twardella D., and Chang-Claude J. Studies on radiosensitivity from an epidemiological point of view-overview of methods and results. Radiother. Oncol. 62 (2002) 249-260
63. Tan X.L., Popanda O., Ambrosone C.B., Kropp S., Helmbold I., von Fournier D., Haase W., Sautter-Bihl M.L., Wenz F., Schmezer P., and Chang-Claude J. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res. Treat. 97 (2006) 255-262
64. Dumont P., Leu J.I., Della III P.A., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33 (2003) 357-365
65. Pim D., and Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int. J. Cancer 108 (2004) 196-199
66. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 411 (2001) 366-374
67. Wood R.D., Mitchell M., Sgouros J., and Lindahl T. Human DNA repair genes. Science 291 (2001) 1284-1289
68. Moullan N., Cox D.G., Angele S., Romestaing P., Gerard J.P., and Hall J. Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 1168-1174
69. Chang-Claude J., Popanda O., Tan X.L., Kropp S., Helmbold I., von Fournier D., Haase W., Sautter-Bihl M.L., Wenz F., Schmezer P., and Ambrosone C.B. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin. Cancer Res. 11 (2005) 4802-4809
70. Brem R., Cox D.G., Chapot B., Moullan N., Romestaing P., Gerard J.P., Pisani P., and Hall J. The XRCC1-77T->C variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage. Carcinogenesis 27 (2006) 2469-2474
71. Shanley S., McReynolds K., Ardern-Jones A., Ahern R., Fernando I., Yarnold J., Evans G., Eccles D., Hodgson S., Ashley S., Ashcroft L., Tutt A., Bancroft E., Short S., Gui G., Barr L., Baildam A., Howell A., Royle G., Pierce L., Easton D., and Eeles R. Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin. Cancer Res. 12 (2006) 7025-7032
72. Popanda O., Tan X.L., Ambrosone C.B., Kropp S., Helmbold I., von Fournier D., Haase W., Sautter-Bihl M.L., Wenz F., Schmezer P., and Chang-Claude J. Genetic polymorphisms in the DNA double-strand break repair genes XRCC3, XRCC2, and NBS1 are not associated with acute side effects of radiotherapy in breast cancer patients. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 1048-1050
73. De Ruyck K., Van Eijkeren M., Claes K., Morthier R., De Paepe A., Vral A., De Ridder L., and Thierens H. Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Int. J. Radiat. Oncol. Biol. Phys. 62 (2005) 1140-1149
74. Kornguth D.G., Garden A.S., Zheng Y., Dahlstrom K.R., Wei Q., and Sturgis E.M. Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants. Int. J. Radiat. Oncol. Biol. Phys. 62 (2005) 665-671
75. Woelfelschneider A., Popanda O., Lilla C., Linseisen J., Mayer C., Celebi O., Debus J., Bartsch H., Chang-Claude J., and Schmezer P. A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. Carcinogenesis (2008) 1758-1764
76. Wiebalk K., Schmezer P., Kropp S., Chang-Claude J., Celebi O., Debus J., Bartsch H., and Popanda O. In vitro radiation-induced expression of XPC mRNA as a possible biomarker for developing adverse reactions during radiotherapy. Int. J. Cancer 121 (2007) 2340-2345
77. Butkiewicz D., Popanda O., Risch A., Edler L., Dienemann H., Schulz V., Kayser K., Drings P., Bartsch H., and Schmezer P. Association between the risk for lung adenocarcinoma and a (-4) G-to-A polymorphism in the XPA gene. Cancer Epidemiol. Biomarkers Prev. 13 (2004) 2242-2246
78. Rose-Ped A.M., Bellm L.A., Epstein J.B., Trotti A., Gwede C., and Fuchs H.J. Complications of radiation therapy for head and neck cancers. The patient's perspective. Cancer Nurs. 25 (2002) 461-467
79. Stokman M.A., Spijkervet F.K., Boezen H.M., Schouten J.P., Roodenburg J.L., and de Vries E.G. Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. J. Dent. Res. 85 (2006) 690-700
80. Scully C., Epstein J., and Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 1. Pathogenesis and prophylaxis of mucositis. Head Neck 25 (2003) 1057-1070
81. Bentzen S.M., and Overgaard J. Patient-to-patient variability in the expression of radiation-induced normal tissue injury. Semin. Radiat. Oncol. 4 (1994) 68-80
82. Kruglyak L. The road to genome-wide association studies. Nat. Rev. Genet. 9 (2008) 314-318
83. West C.M., McKay M.J., Holscher T., Baumann M., Stratford I.J., Bristow R.G., Iwakawa M., Imai T., Zingde S.M., Anscher M.S., Bourhis J., Begg A.C., Haustermans K., Bentzen S.M., and Hendry J.H. Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. Int. J. Radiat. Oncol. Biol. Phys. 62 (2005) 1264-1273
84. Green H., Ross G., Peacock J., Owen R., Yarnold J., and Houlston R. Variation in the manganese superoxide dismutase gene (SOD2) is not a major cause of radiotherapy complications in breast cancer patients. Radiother. Oncol. 63 (2002) 213-216